Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease



Status:Active, not recruiting
Conditions:Neurology, Orthopedic, Hematology, Dermatology
Therapuetic Areas:Dermatology / Plastic Surgery, Hematology, Neurology, Orthopedics / Podiatry
Healthy:No
Age Range:2 - Any
Updated:4/21/2016
Start Date:March 2011

Use our guide to learn which trials are right for you!

A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation

This randomized phase II trial is evaluating how well imatinib mesylate works compared to
rituximab in treating cutaneous sclerosis in patients with chronic graft- versus-host
disease (GVHD). Both imatinib and rituximab have been reported to decrease skin thickening
and improve skin and joint flexibility in people with cutaneous sclerosis due to chronic
GVHD.

PRIMARY OBJECTIVES:

I. To determine the best clinical response rate of cutaneous sclerosis (skin and/or fascial
thickening) after 6 months of initial therapy with either imatinib (imatinib mesylate) or
rituximab.

SECONDARY OBJECTIVES:

I. To determine the best response at either the 3 or 6 month assessment.

II. To determine the response rate at the 3 month assessment.

III. To determine the proportion of subjects who are able to taper corticosteroid after 6
months of imatinib or rituximab therapy.

IV. To determine the incidence of treatment failure to initial treatment with either
imatinib or rituximab.

V. To evaluate if the Scleroderma Health Assessment Questionnaire (SHAQ) findings correlate
with severity of cutaneous sclerosis clinical findings and response to study treatment.

VI. To correlate the detection of antibody against platelet derived growth factor receptor
alpha (PDGFR A) with clinical response.

VII. To correlate change in B cell relevant parameters from baseline to 6 months or early
crossover (antibody levels, skin collagen expression, B cell subsets) with therapeutic agent
and best clinical response while on initial treatment.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive imatinib mesylate by mouth (PO) once daily (QD) for 6 months in the
absence of progression of sclerosis or unacceptable toxicity. Subjects with a significant
clinical response will continue to receive study drug for an additional 6 months.

ARM II: Patients receive rituximab intravenously (IV) on days 1, 8, 15, and 22 (first
cycle). A second cycle of treatment with rituximab is repeated at 3 months for a total of 8
doses of rituximab in the absence of progression of sclerosis or unacceptable toxicity.

Patients with progression, treatment intolerance at any time up to 6 months, or no clinical
response at 6 months will crossover to the other treatment arm.

Inclusion Criteria:

- Diagnosis within the past 18 months of cutaneous sclerosis after hematopoietic cell
transplant (HCT) with sclerotic skin, morphea, myofascial involvement or joint
contractures; must have a score of 2 or greater on the Vienna skin scale in any area,
or a range-of-motion (ROM) score of 5 or less at the shoulder, elbow or wrist, or 3
or less at the ankle

- No medication added for the treatment of graft versus host disease (GVHD) within the
past 4 weeks

- Receiving corticosteroids at a dose greater than required for treatment of adrenal
insufficiency, unless the physician documents why steroids are contraindicated

- Age 2-99 years

- Karnofsky performance status >= 60% at enrollment

- All females of childbearing potential must have a negative serum or urine pregnancy
test =< 7 days prior to starting study therapy

- All females of childbearing potential must agree to use a form of Food and Drug
Administration (FDA) approved contraception from enrollment to one month after study
treatment ends

- Subject has the ability to understand and willingness to sign a written informed
consent document

Exclusion Criteria:

- Total bilirubin > 1.5x upper limit of normal (ULN)

- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 x ULN

- Renal insufficiency (serum creatinine > 2.0 mg/dl)

- Platelets < 30,000/ul or absolute neutrophil count < 1500/ul

- Known hypersensitivity to rituximab or other anti-B cell antibodies

- Known imatinib intolerance or allergy

- Evidence of any active viral, bacterial, or fungal infection that is progressive
despite appropriate treatment

- Hepatitis B surface antigen positive

- Hepatitis B core antibody positive, unless hepatitis B virus (HBV) deoxyribonucleic
acid (DNA) is undetectable

- Hepatitis C antibody positive, unless hepatitis C virus (HCV) ribonucleic acid (RNA)
is undetectable

- Pregnant, lactating, or planning a pregnancy while in the study

- Distal leg skin score 3 or higher as the only manifestation of sclerosis

- Prior treatment of chronic GVHD with imatinib, rituximab, or any other monoclonal
B-cell antibody (e.g. ofatumumab)

- Receipt of imatinib within the previous 6 months for any indication

- Receipt of any monoclonal B-cell antibody (e.g. rituximab, ofatumumab) within the
previous 12 months for any indication

- Treatment with anti-B-cell cellular therapy (e.g. chimeric
antigen-receptor-engineered cells) at any time after transplant

- Current treatment with extracorporeal photopheresis (ECP) at the time of enrollment

- History of psychiatric disorder that would interfere with normal participation in
this study

- Inability or unwillingness of subject and/or parent guardian to provide informed
consent or comply with study protocol

- Use of non-FDA approved drugs within 4 weeks of participation

- Patient with any condition that, in the opinion of the investigator, would interfere
with the subject's ability to comply with the study requirements

- Patients with uncontrolled substance abuse
We found this trial at
12
sites
666 Elm Street
Buffalo, New York 14263
(716) 845-2300
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
2220 Pierce Ave
Nashville, Tennessee 37232
615-936-8422
Vanderbilt-Ingram Cancer Center The Vanderbilt-Ingram Cancer Center, located in Nashville, Tenn., brings together the clinical...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
1100 Fairview Avenue North
Seattle, Washington 98109
206-667-4584
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium The Fred Hutchinson/University of Washington Cancer...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
12902 USF Magnolia Dr
Tampa, Florida 33612
(888) 663-3488
H. Lee Moffitt Cancer Center & Research Institute Moffitt Cancer Center in Tampa, Florida, has...
?
mi
from
Tampa, FL
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
(919) 962-2211
Univ of North Carolina Carolina’s vibrant people and programs attest to the University’s long-standing place...
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
9200 W Wisconsin Ave
Milwaukee, Wisconsin 53226
(414) 805-3666
Froedtert and the Medical College of Wisconsin Froedtert Health combines with the Medical College of...
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials
New York, New York 10021
?
mi
from
New York, NY
Click here to add this to my saved trials
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
13400 E. Shea Blvd.
Scottsdale, Arizona 85259
480-301-8000
Mayo Clinic Arizona Mayo Clinic in Arizona provides medical care for thousands of people from...
?
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
900 Quarry Road Extension
Stanford, California 94305
(650) 723-5111
Stanford University Hospitals and Clinics A LEADER IN THE BIOMEDICAL REVOLUTION , Stanford Medicine has...
?
mi
from
Stanford, CA
Click here to add this to my saved trials